How do we count the cost of autoimmune disease?

June 2011 A question to explore:  How do we count the cost of autoimmune disease? The National Institutes of Health, in its “Progress in Autoimmune Disease Research” Report, states: “The burden of a human disease should be counted not only in terms of dollars spent on health care for people directly affected, but as the more »

New Name for Wegener’s Granulomatosis

May 2011 Granulomatosis with Polyangitis (Wegener’s)”: The New Name for “Wegener’s Granulomatosis” The term “Wegener’s granulomatosis” was introduced to the English language medical literature in 1954.  The name was proposed to honor Dr. Friedrich Wegener.  Dr. Wegener was an early describer of the disease, but not the first describer.  Since the first descriptions, many scientists more »

FDA Approval of Rituxan for Wegener’s and Microscopic Polyangiitis

April 2011 On April 19, 2011, the U.S. Food and Drug Administration approved the drug, Rituxan®, (rituximab) in combination with glucocorticosteroids for the treatment of two forms of ANCA-associated vasculitis: granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rituxan is the first FDA-approved drug for any form of vasculitis, a family of 15+ rare autoimmune diseases more »

NIH Launches Second Phase of Patient Reported Outcomes Initiative

January 2011 The National Institutes of Health (NIH) announced that it is awarding 15 new grants to further develop and test the Patient Reported Outcomes Measurement Information System (PROMIS). Managed by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), PROMIS aims to revolutionize the way patient reported outcome tools are selected and more »